I don't think it is out of the question at all that this trial succeeds at the final. The fact of the matter is the exuberance created by these false models of statistical analysis goosed everyone's expectations of the 2IA - and got a lot of idiots involved in the stock - which probably also got a lot of generalist hedge funds involved in the name also.
I mean, really. How many drugs in Phase 3 are actually halted for efficacy at the 2IA?
Further, they still do have PX-866 which has shown some decent results - so it's not like a market-cap $250 million is crazy. Lots of crap out there trading at higher valuations.
Market Data 
Markets 
AI
